Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Short-term Investments (2016 - 2024)

Myriad Genetics has reported Short-term Investments over the past 15 years, most recently at $4.9 million for Q2 2024.

  • Quarterly Short-term Investments fell 73.94% to $4.9 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Jun 2024, down 73.94% year-over-year, with the annual reading at $8.8 million for FY2023, 84.83% down from the prior year.
  • Short-term Investments was $4.9 million for Q2 2024 at Myriad Genetics, down from $7.4 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $103.2 million in Q1 2022 and troughed at $4.9 million in Q2 2024.
  • The 5-year median for Short-term Investments is $44.0 million (2020), against an average of $46.4 million.
  • Year-over-year, Short-term Investments surged 279.41% in 2022 and then crashed 87.52% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $33.7 million in 2020, then soared by 141.54% to $81.4 million in 2021, then decreased by 28.75% to $58.0 million in 2022, then plummeted by 84.83% to $8.8 million in 2023, then tumbled by 44.32% to $4.9 million in 2024.
  • Per Business Quant, the three most recent readings for MYGN's Short-term Investments are $4.9 million (Q2 2024), $7.4 million (Q1 2024), and $8.8 million (Q4 2023).